Chapter2
1 Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360: 2749–2757.
2 Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 246–259.
3 Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982–991.
4 DeMeo DL, Campbell EJ, Brantly ML, et al. Heritability of lung function in severe alpha-1 antitrypsin deficiency. Hum Hered 2009; 67: 38–45.
5 Dahl M, Hersh CP, Ly NP, et al. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005; 26: 67–76.
6 Campos MA, Wanner A, Zhang G, et al. Trends in the diagnosis of symptomatic patients with α1- antitrypsin deficiency between 1968 and 2003. Chest 2005; 128: 1179– 1186.
7 De Serres FJ. Worldwide racial and ethnic distribution of α1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818– 1829.
8 Luisetti M, Seersholm N. α1-Antitrypsin deficiency 1: epidemiology of α1- antitrypsin deficiency. Thorax 2004; 56: 164–169.
9 Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360–368.
10 Turro E, Astle W, Megy K. Whole-genome sequencing of rare disease patients in a national healthcare system. Nature 2020; 583: 96–102.
11 Said MA, Verweij N, van der Harst P. Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK Biobank study. JAMA Cardiol 2018; 3: 693–702.
12 Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 2019; 364: k5222.
13 UK Biobank. 2007. UK Biobank: Protocol for a large-scale prospective epidemiological resource. www.ukbiobank. ac.uk/wp-content/uploads/2011/11/UK-BiobankProtocol.pdf.
14 Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha1- antitrypsin deficiency. N Engl J Med 1986; 314: 736–739.
15 McBean J, Sable A, Maude J, et al. Alpha1-antitrypsin deficiency panniculitis. Cutis 2003; 71: 205–209.
16 Mahr AD, Edberg JC, Stone JH, et al. Alpha1-antitrypsin deficiency-related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum 2010; 62: 3760–3767.
17 Sun Z, Yang P. Role of imbalance between neutrophil elastase and α1-antitrypsin in cancer development and progression. Lancet Oncol 2004; 5: 182–190.
18 Office for National Statistics (ONS). Key Statistics and Quick Statistics for Local Authorities in the United Kingdom. Newport, Office for National Statistics, 2013; pp. 1–27.
19 Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet 2019; 51: 481–493.
20 Office for National Statistics (ONS). National Population Projections: 2016-based Statistical Bulletin. 2017. www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojecti ons/bulletins/nationalpopu lationprojections/2016basedstatisticalbulletin
21 O’Brien ML, Buist NRM, Murphey WH. Neonatal screening for alpha1-antitrypsin deficiency. J Pediatr 1978; 92: 1006–1010.
22 Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294: 1316–1321.
23 Wang Q, Du J, Yu P, et al. Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis. Sci Rep 2015; 5: 17833.
24 Stoller JK, Sandhaus RA, Turino G, et al. Delay in diagnosis of α1-antitrypsin deficiency: a continuing problem. Chest 2005; 128: 1989–1994.
25 Tejwani V, Nowacki AS, Fye E, et al. The impact of delayed diagnosis of alpha-1 antitrypsin deficiency: the association between diagnostic delay and worsened clinical status. Respir Care 2019; 64: 915–
26 Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis 2016; 10: 72–84.
27 Horváth I, Canotilho M, Chlumský J, et al. Diagnosis and management of α1- antitrypsin deficiency in Europe: an expert survey. ERS Open Res 2019; 5: 00171-2018.
28 Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: Diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J 2017; 50: 1700610.
29 Franciosi AN, Carroll TP, McElvaney NG. Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians. Lancet Respir Med 2019; 7: 1059–1067.
30 Sanders CL, Ponte A, Kueppers F. The effects of inflammation on alpha 1 antitrypsin levels in a national screening cohort. COPD 2018; 15: 10–16.
31 Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189: 419–427.
32 Fadini GP, Menegazzo L, Rigato M, et al. NETosis delays diabetic wound healing in mice and humans. Diabetes 2016; 65: 1061–1071.
33 Dijk W, Kersten S. Regulation of lipoprotein lipase by Angptl4. Trends Endocrinol Metab 2014; 25: 146–155.
34 Ferkingstad E, Oddsson A, Gretarsdottir S, et al. Genome-wide association metaanalysis yields 20 loci associated with gallstone disease. Nat Commun 2018; 9: 5101.
35 Fähndrich S, Biertz F, Karch A, et al. Cardiovascular risk in patients with alpha-1- antitrypsin deficiency. Respir Res 2017; 18: 171.
36 Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe α1-antitrypsin deficiency (PiZZ). Eur Respir J 1999; 13: 247–251.
37 Tanash HA, Nilsson PM, Nilsson JÅ, et al. Clinical course and prognosis of neversmokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008; 63: 1091–1095.
38 DeMeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax 2007; 62: 805–812.
39 Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and healthrelated characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 2017; 186: 1026–1034.
40 Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome–phenome relationship using phenome-wide association studies. Nat Rev Genet 2016; 17: 129–145.
41 Health and Social Care Information Centre. Health Survey for England 2018 Asthma. 2019. healthsurvey.hscic.gov. uk/media/81643/HSE18-Asthma-rep.pdf Date last updated: December 3, 2019. Date last accessed: June 4, 2020.
42 Health and Safety Executive (HSE). 2019. Work-related Chronic Obstructive Pulmonary Disease (COPD) statistics in Great Britain, 2019. https://www.hse.gov.uk/statistics/causdis/copd.pdf.
43 Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186–193.
44 Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19: 249–255.
45 Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995; 151: 369–373.
Chapter3
1. McKee M, Stuckler D. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med. 2020;26(5):640–642.
2. Buitrago-Garcia D, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346.
3. Dooling K, et al. The Advisory Committee on immunization practices’ updated interim recom- mendation for allocation of COVID-19 vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1657–1660.
4. Bubar KM, et al. Model-informed COVID-19 vac- cine prioritization strategies by age and serostatus. Science. 2021;371(6532):916–921.
5. Novelli G, et al. COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. Hum Genomics. 2021;15(1):1–13.
6. O’Driscoll M, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020;590(7844):140–145.
7. Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436.
8. Chaudhry R, et al. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine. 2020;25:100464.
9. Baric RS. Emergence of a highly fit SARS-CoV-2 variant. N Engl J Med. 2020;383(27):2684–2686.
10. Van Der Kolk DM, et al. Penetrance of breast can- cer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: High cancer incidence at older age. Breast Cancer Res Treat. 2010;124(3):643–651.
11. Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490.
12. Feng YCA, et al. Findings and insights from the genetic investigation of age of first reported occurrence for complex disorders in the UK Biobank and FinnGen [preprint]. https://doi.org/10. 1101/2020.11.20.20234302. Posted on medRxiv November 25, 2020.
13. Olarte L, et al. Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics. Arch Neurol. 2006;63(11):1586–1590.
14. The Severe Covid-19 GWAS Group. Genome wide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522–1534.
15. Pairo-Castineira E, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2020;591(7848):92–98.
16. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19 [published online July 8, 2021]. Nature. https://doi. org/10.1038/s41586-021- 03767-x.
17. Kosmicki JA, et al. Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am J Hum Genet. 2021;108(7):1350–1355.
18. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020;587(7835):610–612.
19. Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443.
20. Auton A, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.
21. Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;(3):1–8.
22. Merrill JT, et al. Emerging evidence of a COVID- 19 thrombotic syndrome has treatment implica- tions. Nat Rev Rheumatol. 2020;16(10):581–589.
23. Higuera-de la Tijera F, et al. Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19. Liver Res. 2021;5(1):21–27.
24. Vafadar Moradi E, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am J Emerg Med. 2021;40:11–14.
25. Yan L, et al. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020;2(5):283–288.
26. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
27. Poustchi H, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;21(4):473–481.
28. Vuille-Dit-Bille RN, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015;47(4):693–705.
29. Yao Y, et al. Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID- 19. Signal Transduct Target Ther. 2021;6(1):85.
30. Smieszek SP, Polymeropoulos MH. Role of FYVE and coiled-coil domain autophagy adaptor 1 in severity of COVID-19 1 infection 2 [preprint]. https://doi.org/10.1101/2021.01.22.21250070. Posted on medRxiv January 27, 2021.
31. Payne DJ, et al. The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patients [preprint]. https://doi. org/10.1101/2021.01.25.428125. Posted on bioRxiv January 25, 2021.
32. Khalil BA, et al. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976–988.
33. Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970–979.
34. Liao M, et al. Single-cell landscape of bronchoal- veolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842–844.
35. Fry A, et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026–1034.
36. Griffith GJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11(1):1–12.
37. Miyara M, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19 [preprint]. https://doi.org/10.32388/ WPP19W.3. Posted on Qeios April 21, 2020.
38. Di Maria E, et al. Genetic variants of the human host influencing the coronavirusassociated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. Hum Genomics. 2020;14(1):30.
39. Altshuler DM, et al. Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467(7311):52–58.
40. Marshall JC, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197.
41. Signorelli C, Odone A. Age-specific COVID-19 case-fatality rate: no evidence of changes over time. Int J Public Health. 2020;65(8):1435–1436.
42. Centers for Disease Control and Prevention. People With Certain Medical Conditions. https:// www.cdc.gov/coronavirus/2019-ncov/need- extra-precautions/peoplewith-medical- conditions.html. Updated August 20, 2021. Accessed January 29, 2021.
43. Purcell S, et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet. 2007;81(3):559–575.
44. Downes DJ, et al. Identification of LZTFL1 as a candidate effector gene at a COVID19 risk locus. Nat Genet. 2021;53(11):1606–1615.
Chapter4
1 Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017; 389: 1941–1952.
2 Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496–504. 3 Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. 4 King TE, Bradford WZ, Castro-Bernardini S, et al. A phase
3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
5 Hunninghake GM. Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax 2019; 74: 506–511.
6 Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
7 White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2016; 194: 1242–1251.
8 Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68–73.
9 Neighbors M, Cabanski CR, Ramalingam TR, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med 2018; 6: 615–626.
10 Labrecque JA, Swanson SA. Interpretation and potential biases of Mendelian randomisation estimates with time-varying exposures. Am J Epidemiol 2019; 188: 231–238.
11 Allen RJ, Guillen-Guio B, Oldham JM, et al. Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2020; 201: 564– 574.
12 Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature 2018; 558:73–79.
13 Emilsson V, Ilkov M, Lamb JR, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 2018; 361: 769–773.
14 Davey Smith G, Davies NM, Dimou N, et al. STROBE-MR: guidelines for strengthening the reporting of Mendelian randomisation studies. Peer J Preprints 2019; 7: 27857v.
15 Tam V, Patel N, Turcotte M, et al. Benefits and limitations of genome-wide association studies. Nat Rev Genet 2019; 20: 467–484.
16 Swanson SA, Hernan MA. The challenging interpretation of instrumental variable estimates under monotonicity. Int J Epidemiol 2018; 47: 1289–1297.
17 Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018; 362: k601.
18 Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7: e34408.
19 Burgess S, Butterworth A, Thompson SG. Mendelian randomisation analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658–665.
20 Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 2014; 10: e100438.
21 Hormozdiari F, van de Bunt M, Segrè AV, et al. Colocalization of GWAS and eQTL signals detects target genes. Am J Hum Genet 2016; 99: 1245–1260.
22 Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualisation of genomewide association scan results. Bioinformatics 2010; 26: 2336–2337.
23 Yavorska OO, Burgess S. MendelianRandomisation: an R package for performing Mendelian randomisation analyses using summarized data. Int J Epidemiol 2017; 46: 1734– 1739.
24 Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomisation: comparison of allele score and summarized data methods. Stat Med 2016; 35: 1880–1906.
25 Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics 2016; 32: 3207–3209.
26 Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics 2019; 35: 4851–4853.
27 Yang IV, Coldren CD, Leach SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 2013; 68: 1114– 1121.
28 Habermann AC, Gutierrez AJ, Bui LT, et al. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Sci Adv 2020; 6: eaba1972.
29 Adams TS, Schupp JC, Poli S, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv 2020; 6: eaba1983.
30 Benner C, Spencer CCA, Havulinna AS, et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics 2016; 32: 1493–1501.
31 Nongmaithem SS, Joglekar CV, Krishnaveni GV, et al. GWAS identifies populationspecific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians. Hum Mol Genet 2017; 26: 2551–2564.
32 Yao C, Chen G, Song C, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun 2018; 9: 3268.
33. He M, Wu C, Xu J, et al. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and alpha fetoprotein and their associations with cancer risk. Gut 2014; 63: 143–151.
34. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 2017; 13: e1007081.
35. Todd JL, Neely ML, Overton R, et al. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res 2019; 20: 227.
36. Parimon T, Yao C, Stripp BR, et al. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci 2020; 21: 2269.
37. Plantier L, Crestani B, Wert SE, et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax 2011; 66: 651–657.
38. Manousaki D, Mokry LE, Ross S, et al. Mendelian randomisation studies do not support a role for vitamin D in coronary artery disease. Circ Cardiovasc Genet 2016; 9: 349– 356.
39. Manson JAE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380: 33–44.
40. Holmes MV, Smith GD. Dyslipidaemia: revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol 2017; 14: 635–636.
41. Holmes MV, Richardson TG, Ference BA, et al. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol 2021; 18: 435–453.
42. Landray M. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637–1645.
43 Larsson SC, Burgess S, Gill D. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia. Eur Respir J 2021: 57: 2003545.
44. Fanidi A, Carreras-Torres R, Larose TL, et al. Is high vitamin B12 status a cause of lung cancer? Int J Cancer 2019; 145: 1499–1503.
45. Mokry LE, Ahmad O, Forgetta V, et al. Mendelian randomisation applied to drug development in cardiovascular disease: a review. J Med Genet 2015; 52: 71–79.
46. Mathai SK, Pedersen BS, Smith K, et al. Desmoplakin variants are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 193: 1151–1160.
47. Moore C, Blumhagen RZ, Yang IV, et al. Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200: 199–208.
48. Nance T, Smith KS, Anaya V, et al. Transcriptome analysis reveals differential splicing events in IPF lung tissue. PLoS One 2014; 9: e92111.
49. Dupuy F, Germot A, Marenda M, et al. α1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently. Mol Biol Evol 2002; 19: 815–824.
50. Johnson DC. Airway mucus function and dysfunction. N Engl J Med 2011; 364: 978.
51. Corfield AP. Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 2015; 1850: 236–252.
52. Janssen WJ, Stefanski AL, Bochner BS, et al. Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur Respir J 2016; 48: 1201–1214.
53. de Mattos LC. Structural diversity and biological importance of ABO, H, Lewis and secretor histo-blood group carbohydrates. Rev Bras Hematol Hemoter 2016; 38: 331–340.
54. Kerr SC, Fischer GJ, Sinha M, et al. FleA expression in Aspergillus fumigatus is recognized by fucosylated structures on mucins and macrophages to prevent lung infection. PLoS Pathogens 2016; 12: e1005555.
55. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503–1512.
56. Hancock LA, Hennessy CE, Solomon GM, et al. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nat Commun 2018; 9: 5363.
57. Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med 2017; 5: 946–955.
58. Kawai S, Suzuki K, Nishio K, et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer 2008; 123: 2880–2884.
59. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
60 Rusanov V, Kramer MR, Raviv Y, et al. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest 2012; 141: 1047–1054.
61 Raffield LM, Dang H, Pratte KA, et al. Comparison of proteomic assessment methods in multiple cohort studies. Proteomics 2020; 20: 1900278.
Chapter5
1. Johns Hopkins University of Medicine. Coronavirus Resource Center. https://coronavirus.jhu.edu/ (2020).
2. Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2020).
3. Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
4. Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330–1341 (2020).
5. Beigel, J. H., Tomashek, K. M. & Dodd, L. E. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. 383, 994 (2020).
6. Cavalcanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19. N. Engl. J. Med. 383, 2041–2052 (2020).
7. Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
8. Cook, D. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a fivedimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).
9. Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
10. Filbin, M. R. et al. Plasma proteomics reveals tissue-specific cell death and mediators of cell–cell interactions in severe COVID-19 patients. Preprint at bioRxiv https://doi.org/10.1101/2020.11.02.365536 (2020).
11. Davey Smith, G., Ebrahim, S., Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1–22 (2003).
12. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).
13. Lawlor, D. A., Tilling, K. & Smith, G. D. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).
14. COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718 (2020).
15. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).
16. Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018).
17. Pietzner, M. et al. Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nat. Commun. 11, 6397 (2020).
18. Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 13, e1006706 (2017).
19. Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018).
20. Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat. Commun. 8, 14357 (2017).
21. COVID-19 Host Genetics Initiative. https://www.covid19hg.org/results/ (2021).
22. Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in Covid-19. Nature https://doi.org/10.1038/s41586-020-03065-y (2020).
23. Staley, J. R. et al. PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics 32, 3207–3209 (2016).
24. Prüfer, K. et al. A high-coverage Neandertal genome from Vindija Cave in Croatia. Science 358, 655–658 (2017).
25. Meyer, M. et al. A high-coverage genome sequence from an archaic Denisovan individual. Science 338, 222–226 (2012).
26. Sams, A. J. et al. Adaptively introgressed Neandertal haplotype at the OAS locus functionally impacts innate immune responses in humans. Genome Biol. 17, 246 (2016).
27. Li, H. et al. Identification of a Sjögren’s syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genet. 13, e1006820 (2017).
28. Liu, X. et al. A functional variant in the OAS1 gene is associated with Sjögren’s syndrome complicated with HBV infection. Sci. Rep. 7, 17571 (2017).
29. Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 50, 151–158 (2018).
30. Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
31. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
32. Hornung, V., Hartmann, R., Ablasser, A. & Hopfner, K. P. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat. Rev. Immunol. 14, 521–528 (2014).
33. Kristiansen, H. et al. Extracellular 2′–5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J. Virol. 84, 11898–11904 (2010).
34. Zeberg, H. & Pääbo, S. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. Proc. Natl Acad. Sci. USA 118, e2026309118 (2021).
35. Mendez, F. L., Watkins, J. C. & Hammer, M. F. Neandertal origin of genetic variation at the cluster of OAS immunity genes. Mol. Biol. Evol. 30, 798–801 (2013).
36. Bonnevie-Nielsen, V. et al. Variation in antiviral 2′–5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a spliceacceptor site in the OAS1 gene. Am. J. Hum. Genet. 76, 623–633 (2005).
37. Carey, C. M. et al. Recurrent loss-of-function mutations reveal costs to OAS1 antiviral activity in primates. Cell Host Microbe 25, 336–343 (2019).
38. Zeberg, H. & Pääbo, S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 587, 610–612 (2020).
39. Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
40. Min, J.-Y. & Krug, R. M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2′–5′ oligo (A) synthetase/RNase L pathway. Proc. Natl Acad. Sci. USA 103, 7100–7105 (2006).
41. Hu, B. et al. Cellular responses to HSV-1 infection are linked to specific types of alterations in the host transcriptome. Sci. Rep. 6, 28075 (2016).
42. Lim, J. K. et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5, e1000321 (2009).
43. Simon-Loriere, E. et al. High anti-dengue virus activity of the OAS gene family is associated with increased severity of dengue. J. Infect. Dis. 212, 2011–2020 (2015).
44. Hamano, E. et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem. Biophys. Res. Commun. 329, 1234–1239 (2005).
45. Cheng, G. et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am. J. Respir. Cell Mol. Biol. 45, 480–488 (2011).
46. Harari, D., Orr, I., Rotkopf, R., Baranzini, S. E. & Schreiber, G. A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis. Hum. Mol. Genet. 24, 3192–3205 (2014).
47. Lin, F. & Young, H. A. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 25, 369–376 (2014).
48. Arabi, Y. M. et al. Interferon beta-1b and lopinavir–ritonavir for Middle East respiratory syndrome. N. Engl. J. Med. 383, 1645–1656 (2020).
49. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19— interim WHO SOLIDARITY trial results. N. Engl. J. Med. 384, 497–511 (2021).
50. Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2020).
51. Wood, E. R. et al. The role of phosphodiesterase 12 (PDE12) as a negative regulator of the innate immune response and the discovery of antiviral inhibitors. J. Biol. Chem. 290, 19681–19696 (2015).
52. Silverman, R. H. & Weiss, S. R. Viral phosphodiesterases that antagonize doublestranded RNA signaling to RNase L by degrading 2-5A. J. Interferon Cytokine Res. 34, 455– 463 (2014).
53. Zhao, L. et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 11, 607–616 (2012).
54. Zhang, R. et al. Homologous 2′,5′-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. Proc. Natl Acad. Sci. USA 110, 13114–13119 (2013).
55. Li, Y. et al. SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes. Preprint at bioRxiv https://doi.org/10.1101/2020.09.24.312553 (2020).
56. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample Mendelian randomization. Genet. Epidemiol. 40, 597–608 (2016).
57. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
58. Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
59. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
60. Candia, J. et al. Assessment of variability in the SOMAscan assay. Sci. Rep. 7, 14248 (2017).
61. SomaLogic. Short Technical Note. https://somalogic.com/wpcontent/uploads/2019/07/Short-Technical-Note-SOMAmer-specificity.pdf (2019).
62. Centers for Disease Control and Prevention. Duration of isolation and precautions for adults with COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/durationisolation.html (2021).
63. Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2, e13–e22 (2020).
論文の公開元へ
